Market Trends of Multiplex Assays Industry
Multiplex Real-Time PCR Segment is Expected to Hold a Major Share in the Multiplex Assays Market
Multiplex polymerase chain reaction (PCR) is the process in which more than one target sequence can be amplified by including more than one pair of primers in the reaction. This process amplifies DNA in samples using multiple primers and a temperature-mediated DNA polymerase in a thermal cycler. Some of the advantages of multiplex qPCR include higher throughput, lower reaction costs, and preservation of scarce sample materials. Besides, a set of primers can be used as an internal control in multiplex PCR which has the benefit of eliminating the risk of false positives or negatives.
The multiplex polymerase chain reaction segment is expected to witness significant growth over the forecast period owing to the factors such as rising R&D activities, and various strategies such as product launches adopted by key market players.
The use of multiplex assays in determining pathogenic mutations in reproductive genetic testing is increasing. For instance, according to an article published in Nature Journal, in January 2022, a carrier screening assay, a type of reproductive genetic testing for couples for assessing the risk of passing on certain genetic conditions to offspring, for 448 pathogenic mutations was developed using capillary electrophoresis-based multiplex PCR technology. The capillary electrophoresis-based multiplex PCR assay demonstrated sensitivity, specificity, and accuracy of 97.4%, 100%, and 99.6%, respectively, in detecting the specific variants. Thus, the high accuracy offered by multiplex assays in genetic testing is anticipated to fuel the segment growth.
Additionally, as per an article published in PLOS One, in April 2021, a multiplex real-time reverse transcription polymerase chain reaction (rRT-PCR) assays was developed for the detection of SARS-COV-2, that simultaneously targets two viral genes (RdRP and E) and a human gene (RP) as an internal control by using the Applied Biosystems 7500 Fast Real-Time PCR instrument. It has been observed that the multiplex rRT-PCR method used for the detection of SARS-CoV-2 has provided an accurate, reliable, and easy-to-use SARS-CoV-2 diagnostic test. As per the same source, the assay is efficient to detect three genes in the same reaction tube and allows working with large numbers of patients using less PCR reagent. Thus, such advantages offered by the multiplex PCR method are expected to increase its adoption in detecting other viral infections, hence contributing to segment growth.
Furthermore, the rising new product launches increase the availability of novel products in the market which is also contributing to segment growth. For instance, in July 2022, Bio-Rad Laboratories launched CFX Opus Deepwell Real-Time PCR Detection System to support researchers in developing nucleic acid detection assays. The system can multiplex up to five targets simultaneously and supports fluorescence resonance energy transfer applications. Also, in May 2022, Cipla Limited in partnership with Genes2Me Pvt. Ltd launched an RT-Direct multiplex COVID-19 RT PCR Test kit. This launch assists the company to expands its diagnostics offering to bring more advanced and innovative products.
Therefore, owing to the aforementioned factors, the studied segment is expected to grow over the forecast period.
North America is Expected to Have the Significant Market Share Over the Forecast Period
North America is expected to hold a significant share in the market over the forecast period owing to the factors such as the growing burden of chronic diseases such as HIV, CNS disorders, gastrointestinal disorders, and others along with the rising adoption of multiplex assays over single assays, increasing product approvals, and investments.
The rising prevalence of various diseases such as cancer, cardiovascular diseases, influenza, Alzheimer's disease, and others among the population raises the demand for diagnosing multiple biomarkers for the detection of diseases. This in turn is anticipated to boost the market growth. For instance, according to the 2023 statistics published by ACS, about 19,58,310 new cancer cases are expected to be diagnosed in the United States in 2023. Additionally, as per 2022 statistics published by the Canadian Cancer Society, about 233,900 people were diagnosed with cancer in Canada in 2022. Also, according to the 2022 statistics published by AHA, more than 130 million adults in the United States are expected to have some type of heart disease by 2035. Thus, the expected increase in the population suffering from cancer and heart diseases is anticipated to fuel the demand for multiplex assays to simultaneously analyze multiple biomarkers from a single sample, thereby contributing to the market growth.
Furthermore, with the increasing company focus on adopting various key strategies such as collaboration, partnerships, agreements, and product launches, the studied market is expected to grow over the forecast period. For instance, in April 2022, Bruker Corporation launched a unique LiquidArray multiplex PCR assay that detects seven major pathogens causing Sexually Transmitted Infections (STIs). Also, in January 2022, Health Canada approved Seegene's Allplex SARS CoV-2 FluA/FluB/RSV assay, a multiplex real-time-PCR assay designed to facilitate simultaneous amplification and differentiation of respiratory symptoms.
Therefore, owing to the aforementioned factors, the studied segment is expected to grow over the forecast period.
